News
![Agilent Receives FDA Approval for PD-L1 Companion Diagnostic on Dako Omnis](/assets/news/news18-f135f6c168ef56d2b112890081403b0a310104acfadbf4a8f72634bd390e98ac.png)
Agilent Receives FDA Approval for PD-L1 Companion Diagnostic on Dako Omnis
Agilent Technologies Inc. (NYSE: A) today announced that the U.S. Food and Drug Administration has approved the company’s PD-L1 IHC 22C3 pharmDx as a companion diagnostic (CDx) to identify patients
![Quidel’s Lyra® Direct SARS-CoV-2 Assay Submitted for Emergency Use Authorization for Molecular Detection of COVID-19, Without Extraction Step](/assets/news/news19-14feaf1b3ac689101974b5354f2ab8bb5cb2e7cb49a06b120b8491e9ebba31f4.png)
Quidel’s Lyra® Direct SARS-CoV-2 Assay Submitted for Emergency Use Authorization for Molecular Detection of COVID-19, Without Extraction Step
Quidel Corporation (NASDAQ: QDEL) (“Quidel”), a provider of rapid diagnostic testing solutions, cellular-based virology assays and molecular diagnostic systems, announced today that Quidel has
![Gilead Sciences: Einfach kein entscheidender Durchbruch!](/assets/news/news17-d49b9ce9c87babddea210274f0f8d00a1cf706146ef6382020cc7ece83b76f6c.png)
Gilead Sciences: Einfach kein entscheidender Durchbruch!
Die Aktie von Gilead Sciences (WKN: 885823) steht zuletzt, aufgrund der Covid-19-Pandemie, immer wieder im Mittelpunkt des Anlegerinteresses (wir berichteten). So beflügelte die Aktie kürzlich sogar
![Agilent Signs Sponsorship Agreement with My Green Lab](/assets/news/news7-ff65ae96e2a4b99929975e34f30f51b3393455f312fc86852d9fc8020c5054eb.png)
Agilent Signs Sponsorship Agreement with My Green Lab
Agilent Technologies Inc. (NYSE: A) announced today that it has become a top-level sponsor of My Green Lab, a nonprofit organization dedicated to improving the sustainability of scientific
![Veeva Introduces New Capabilities for Remote Drug Sampling in Veeva CRM Engage Meeting](/assets/news/news6-ad07925a95156ae03dbe17caf44a9dc29f254ff2c2a42c7678d35288ad55cec8.png)
Veeva Introduces New Capabilities for Remote Drug Sampling in Veeva CRM Engage Meeting
Veeva Systems (NYSE: VEEV) today introduced new remote sampling capabilities in Veeva CRM Engage Meeting. Remote sampling enables field reps to capture and fulfill healthcare professionals’ (HCPs)
![Quidel to Hold First Quarter 2020 Financial Results Conference Call on May 6th, 2020](/assets/news/news19-14feaf1b3ac689101974b5354f2ab8bb5cb2e7cb49a06b120b8491e9ebba31f4.png)
Quidel to Hold First Quarter 2020 Financial Results Conference Call on May 6th, 2020
Quidel Corporation (NASDAQ: QDEL), a provider of rapid diagnostic testing solutions, cellular-based virology assays and molecular diagnostic systems, will report first quarter 2020 financial
![Illumina Makes Software Toolkit Available Free of Charge to Support Worldwide Efforts to Combat COVID-19](/assets/news/news3-3816cd3656012f9a06bae00ff06108b383643da017a8247fff474f84ea8a7c5a.png)
Illumina Makes Software Toolkit Available Free of Charge to Support Worldwide Efforts to Combat COVID-19
Illumina, Inc. (NASDAQ: ILMN) announces the Illumina SARS-CoV-2 Data Toolkit, a new suite of data analysis tools and workflow functionality for researchers working with the virus using
![Illumina Reports Preliminary Revenue for First Quarter of Fiscal Year 2020](/assets/news/news19-14feaf1b3ac689101974b5354f2ab8bb5cb2e7cb49a06b120b8491e9ebba31f4.png)
Illumina Reports Preliminary Revenue for First Quarter of Fiscal Year 2020
Illumina, Inc. (NASDAQ: ILMN) today announced preliminary revenue for the first quarter of fiscal year 2020 and withdrew its 2020 guidance.
Subject to quarter-end closing adjustments, the Company
![Agilent Technologies Provides Update on COVID-19 Impact; Sets Second-Quarter Earnings Call for May 21](/assets/news/news11-1ebbf8540812dc8f080ecfeb67ce19c492651a7c439bd800cec2630c3a04a840.png)
Agilent Technologies Provides Update on COVID-19 Impact; Sets Second-Quarter Earnings Call for May 21
Agilent Technologies, Inc. (NYSE: A) today announced that due to the expanded and evolving nature of the COVID-19 pandemic and resulting effects on customer operations, it is withdrawing its
![Pfizer Advances Battle Against COVID-19 on Multiple Fronts](/assets/news/news15-207f60e93f55a63563671c62b1e07d0bc426e50a03c286a608f29c8138f4f1de.png)
Pfizer Advances Battle Against COVID-19 on Multiple Fronts
Pfizer Inc. (NYSE: PFE) today announced important advances in the battle against the global COVID-19 pandemic.
As outlined in Pfizer’s five-point plan, the company has been collaborating across
![Pfizer and BioNTech Announce Further Details on Collaboration to Accelerate Global COVID-19 Vaccine Development](/assets/news/news13-125fa69a38b6955d740c18f7e750c42a3317f6873eded3044187d2ece3aa0ac7.png)
Pfizer and BioNTech Announce Further Details on Collaboration to Accelerate Global COVID-19 Vaccine Development
BioNTech SE (Nasdaq: BNTX, “BioNTech” or “the Company”), and Pfizer Inc. (NYSE: PFE) today disclosed additional details of their collaboration to advance candidates from BioNTech’s mRNA vaccine
![Portfoliocheck: Mit United Health spielt Andreas Halvorsen die Gesundheitskarte](/assets/news/news7-ff65ae96e2a4b99929975e34f30f51b3393455f312fc86852d9fc8020c5054eb.png)
Portfoliocheck: Mit United Health spielt Andreas Halvorsen die Gesundheitskarte
![U.S. FDA Approves BRAFTOVI® (Encorafenib) in Combination with Cetuximab for the Treatment of BRAFV600E-Mutant Metastatic Colorectal Cancer (CRC) After Prior Therapy](/assets/news/news13-125fa69a38b6955d740c18f7e750c42a3317f6873eded3044187d2ece3aa0ac7.png)
U.S. FDA Approves BRAFTOVI® (Encorafenib) in Combination with Cetuximab for the Treatment of BRAFV600E-Mutant Metastatic Colorectal Cancer (CRC) After Prior Therapy
Pfizer Inc. (NYSE: PFE) today announced that the U.S. Food and Drug Administration (FDA) has approved BRAFTOVI® (encorafenib) in combination with cetuximab (marketed as ERBITUX®) for the treatment
![Pfizer to Hold Virtual-Only 2020 Annual Meeting of Shareholders](/assets/news/news19-14feaf1b3ac689101974b5354f2ab8bb5cb2e7cb49a06b120b8491e9ebba31f4.png)
Pfizer to Hold Virtual-Only 2020 Annual Meeting of Shareholders
Pfizer Inc. (NYSE: PFE) today announced that its 2020 Annual Meeting of Shareholders will be held in a virtual-only format due to continued public health concerns related to coronavirus / COVID-19
![Veeva Announces Alliances for Digital Field Engagement](/assets/news/news2-a19c21d90ec8043c932052617f43da76ea8e48ecd096318e237ea24d69a5c8b8.png)
Veeva Announces Alliances for Digital Field Engagement
Veeva Systems (NYSE:VEEV) today announced industry alliances to accelerate the industrywide shift toward digital engagement. Together with Accenture, Deloitte, and other alliance partners, Veeva is
![Pfizer and The Pfizer Foundation Donate $40 Million in Charitable Grants, Expand Product Access and Mobilize Colleagues to Combat COVID-19 Pandemic](/assets/news/news13-125fa69a38b6955d740c18f7e750c42a3317f6873eded3044187d2ece3aa0ac7.png)
Pfizer and The Pfizer Foundation Donate $40 Million in Charitable Grants, Expand Product Access and Mobilize Colleagues to Combat COVID-19 Pandemic
Pfizer Inc. (NYSE: PFE) and The Pfizer Foundation today announced the commitment of $40 million in medical and charitable cash grants to help combat the global health effects of the COVID-19
![Pfizer Receives European Approval for Oncology Biosimilar, RUXIENCE™ (rituximab)](/assets/news/news6-ad07925a95156ae03dbe17caf44a9dc29f254ff2c2a42c7678d35288ad55cec8.png)
Pfizer Receives European Approval for Oncology Biosimilar, RUXIENCE™ (rituximab)
Pfizer Inc. (NYSE: PFE) today announced that the European Commission (EC) has approved RUXIENCE™ (rituximab), a monoclonal antibody (mAb) and biosimilar to MabThera® (rituximab), for the treatment
![Susan Desmond-Hellmann Elected to Pfizer’s Board of Directors](/assets/news/news15-207f60e93f55a63563671c62b1e07d0bc426e50a03c286a608f29c8138f4f1de.png)
Susan Desmond-Hellmann Elected to Pfizer’s Board of Directors
Pfizer Inc. (NYSE: PFE) today announced the election of Dr. Susan Desmond-Hellmann to its Board of Directors, effective immediately. Dr. Desmond-Hellmann, age 62, was also appointed to the
![Dexcom Schedules First Quarter 2020 Earnings Release and Conference Call for April 28, 2020 at 4:30 p.m. Eastern Time](/assets/news/news1-f26f2455ece0c3cbea64441818e795358cadddddb27e796f883ae2bd06f66139.png)
Dexcom Schedules First Quarter 2020 Earnings Release and Conference Call for April 28, 2020 at 4:30 p.m. Eastern Time
DexCom, Inc. (NASDAQ:DXCM) today announced that it plans to release its first quarter 2020 financial results after market close on Tuesday, April 28, 2020. Management will hold a conference call to
![Free Remote Monitoring Solution Now Available for All Clinical Research Sites](/assets/news/news10-be520e400538f920c1970757e43cd0aa35625c1095be243829bb7a152346bd95.png)
Free Remote Monitoring Solution Now Available for All Clinical Research Sites
Veeva Systems (NYSE: VEEV) today announced new remote monitoring capabilities in Veeva SiteVault Free for source document review and verification in clinical trials. Veeva SiteVault Free gives
![Medical Professionals Across Merck & Co., Inc., Pfizer Inc., and Eli Lilly and Company Activate to Support Health Systems, First Responders and Patients Amid COVID-19 Pandemic](/assets/news/news7-ff65ae96e2a4b99929975e34f30f51b3393455f312fc86852d9fc8020c5054eb.png)
Medical Professionals Across Merck & Co., Inc., Pfizer Inc., and Eli Lilly and Company Activate to Support Health Systems, First Responders and Patients Amid COVID-19 Pandemic
Merck & Co., Inc., (NYSE: MRK), Pfizer Inc. (NYSE: PFE), and Eli Lilly and Company (NYSE: LLY) today announced medical service volunteer programs to enable employees who are licensed medical
![Agilent Introduces New Handheld Raw Material ID System for Pharmaceutical Manufacturers](/assets/news/news18-f135f6c168ef56d2b112890081403b0a310104acfadbf4a8f72634bd390e98ac.png)
Agilent Introduces New Handheld Raw Material ID System for Pharmaceutical Manufacturers
Agilent Technologies Inc. (NYSE: A) today announced the launch of the newest instrument in its Raman technology portfolio. The new Agilent Vaya Raman raw material identity verification system is a
![Agilent Technologies to Change Location of Annual Meeting](/assets/news/news14-e52b56a6adda780de8ab40d75cabe14dcfa77fc9676e986401297a29e68c991e.png)
Agilent Technologies to Change Location of Annual Meeting
Agilent Technologies, Inc. (NYSE: A) today filed a supplement to its proxy statement with the Securities and Exchange Commission announcing a change of location for its previously adjourned annual
![Agilent Announces New Class 1 Triple Quadrupole LC/MS System](/assets/news/news7-ff65ae96e2a4b99929975e34f30f51b3393455f312fc86852d9fc8020c5054eb.png)
Agilent Announces New Class 1 Triple Quadrupole LC/MS System
Agilent Technologies Inc. (NYSE: A) today introduced the Agilent K6460S Clinical Edition TQ LC/MS system, designed to improve in vitro diagnostic workflows in clinical labs.
Agilent’s
![Pfizer Completes $1.25 Billion Sustainability Bond for Social and Environmental Impact](/assets/news/news7-ff65ae96e2a4b99929975e34f30f51b3393455f312fc86852d9fc8020c5054eb.png)
Pfizer Completes $1.25 Billion Sustainability Bond for Social and Environmental Impact
Pfizer Inc. (NYSE: PFE) today announced the completion of a $1.25 billion ten-year “sustainability” bond paying interest semi-annually of 2.625 percent and maturing April 1, 2030. This is Pfizer’s